Benralizumab

Benralizumab
SKU
BPS82843-2
Packaging Unit
2 mg
Manufacturer
BPS Bioscience

Availability: loading...
Price is loading...
Products from BPS Bioscience require a minimum order value above 400€

Background: IL-5 (interleukin-5) is a pro-inflammatory protein that functions as an intermediary cytokine in the TH2 (T helper 2) cells response in asthma and other eosinophilic allergic diseases. IL-5 is produced by TH2 cells and ILC2 (group 2 innate lymphoid cells) cells in response to stimulation by alarmins such as TSLP (thymic stromal lymphopoietin) or IL-33, which initiate the inflammatory cascade. IL-5 functions by promoting eosinophil maturation, activation, and migration into target tissues. It binds to the IL-5 specific cell surface receptor IL-5RA (IL-5 receptor alpha) and further recruits the common beta chain receptor (CSF2RB) to initiate downstream signaling through JAK1/2 (Janus kinase 1/2) and STAT5. Activated eosinophils contribute to airway damage through degranulation, resulting in the release of pro-inflammatory cytokines and enzymatic mediators contributing to local inflammation and tissue damage.IL-5 signaling plays a critical role in allergic and eosinophilic asthma subtypes and has been an active area for drug discovery. Antibodies targeting both IL-5 ligand and IL-5 Receptor (IL-5RA) are FDA (Food and Drug Administration) approved for the treatment of severe eosinophilic asthma and other eosinophilic conditions. These antibodies function by neutralizing IL-5-mediated signaling in eosinophils. Additionally, IL-5RA targeting antibodies and CAR (chimeric antigen receptor)-T cells can induce immune-mediated cytotoxicity of IL-5RA-expressing cells, including eosinophils through ADCC (antibody-dependent cellular cytotoxicity) and CAR-T cell mediated killing respectively.

Description: Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.1

Format: Aqueous buffer solution.

Formulation: Sterile solution containing histidine, histidine hydrochloride monohydrate, trehalose dehydrate, and polysorbate 20.

Purity: ≥90%

Storage Stability: Store at 4°C for 2 years, do not freeze.

Target: IL-5Rα

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: Not applicable (BSL-1)

References: 1. Menzies-Gow A, et al., 2019 ERJ Open Res.  5(3): 00009-2019.
More Information
SKU BPS82843-2
Manufacturer BPS Bioscience
Manufacturer SKU 82843-2
Package Unit 2 mg
Quantity Unit STK
Clonality Monoclonal
Isotype Human IgG1 Kappa
Product information (PDF)
×
MSDS (PDF)
×